康聖環球(09960.HK)中期經調整淨利潤2896.6萬元 研發成本同比增加33.3%
格隆匯8月30日丨康聖環球(09960.HK)發佈公吿,截至2021年6月30日止6個月,實現收益人民幣4.38億元,同比增長2.0%;毛利人民幣2.34億元,同比增長9.6%;經調整淨利潤人民幣2896.6萬元。
報吿期內,集團的研發成本由截至2020年6月30日止六個月的人民幣3180萬元增加33.3%至2021年同期的人民幣4240萬元。有關增加主要由於集團於2021年上半年依託先進技術平台在血液學檢測、腫瘤學檢測、遺傳病檢測、傳染病檢測和自身免疫性疾病檢測等多個疾病領域推出46個新的研究項目,導致集團的員工成本和原材料成本增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.